RNA-sequencing of tamoxifen-resistant and -sensitive breast cancer cell lines.. RNA-sequencing of tamoxifen-resistant and -sensitive breast cancer cell lines.

We performed RNA-sequencing on 7 tamoxifen-resistant (MCF-7 Tam1, T-47D Tam1, T-47D Tam2, ZR-75-1 Tam1, ZR-75-1 Tam2, BT474 Tam1 and BT-474 Tam2) and their isogenic parental (MCF-7, T-47D, ZR-75-1 and BT-474) breast cancer cell lines. The tamoxifen-resistant cell lines were generated from the parentel cell lines by continuous administration of 1 µM 4-OH-tamoxifen for eight to twelve months. RNA- sequencing was performed to determine the changes in the expression of genes in the resistant clones as well as pathways. In addition, we compared the expression changes of the cell lines with those of the GSE58708 data set which we reanalyzied in our pipeline. Overall design: Paired-end RNA-sequencing of 7 tamoxifen-resistant (MCF-7 Tam1, T-47D Tam1, T-47D Tam2, ZR-75-1 Tam1, ZR-75-1 Tam2, BT474 Tam1 and BT-474 Tam2) and their isogenic parental (MCF-7, T-47D, ZR-75-1 and BT-474) breast cancer cell lines and re-analysis of GSE58708.

我们对7株他莫昔芬耐药（MCF-7 Tam1、T-47D Tam1、T-47D Tam2、ZR-75-1 Tam1、ZR-75-1 Tam2、BT474 Tam1及BT-474 Tam2）及其同基因亲本（MCF-7、T-47D、ZR-75-1和BT-474）乳腺癌细胞系开展了RNA测序（RNA-sequencing）。该他莫昔芬耐药细胞系通过以1 μM浓度的4-羟基他莫昔芬（4-OH-tamoxifen）持续给药8至12个月，由亲本细胞系诱导构建而来。本研究通过RNA测序明确耐药克隆的基因表达变化及相关通路改变。此外，我们将本研究细胞系的表达变化与我们通过自有分析流程重新解析的GSE58708数据集的表达变化进行了对比。总体实验设计：对7株他莫昔芬耐药乳腺癌细胞系及其同基因亲本细胞系进行双端RNA测序（paired-end RNA-sequencing），并对GSE58708数据集开展重新分析。